A natural antibacterial molecule shows clinical promise. Its unusual binding site is on an excellent target: ...
PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...
Maze Therapeutics IPOs at $487M, targeting APOL1 Kidney Disease with MZE829 in Phase 2. Click here to read an analysis of MAZE stock now.
Over the past decades, bronchiectasis has been neglected, despite the global burden.1,2 To date, better diagnosis due to easy ...
Dairy is typically seen as a food group that has a ‘health halo ... Sources: 1. Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitroAuthors: ...
Neurosciences Unit, Institute of Child Health, University College London Medical School, 30 Guilford Street, London WC1N 1EH, UK Dr Rod C Scott, The Wolfson Centre, Mecklenburgh Square, London WC1N ...